Commented Articles
PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.
Fibrosis-4 index reflects right ventricular function and prognosis in HFpEF
Authors: Nakashima M, Sakuragi S, Miyoshi T, et al.
Published in ESC Heart Fail 2021
The authors investigated the prognostic implication of the FIB-4 index regarding right ventricular dysfunction in patients with HFpEF.
Read MoreNAFL: FIB-4, a strong predictor of both all-cause mortality and liver-related adverse outcomes
Authors: Vieira Barbosa J, Milligan S, Frick A, et al.
Published in Hepatol Commun 2022
The authors analysed data on 30 million patients categorised into three diagnostic groups: NAFLD, NASH, and at risk of NASH.
Read MoreFrom NAFLD to MAFLD in terms of nurse perspective
Authors: Clayton M, Fabrellas N, Luo J, et al.
Published in Liver Int 2021
An international consensus panel has produced an influential report renaming the disease from NAFLD to MAFLD and suggesting how the disease should be diagnosed.
Read MoreMAFLD: a milestone in the history of fatty liver disease
Authors: Alharthi J, Eslam M.
Published in Hepatobiliary Surg Nutr 2021
Our growing understanding of the natural history and pathogenesis of MAFLD and the predominant role of metabolic dysfunction in this disease have evoked efforts to redefine fatty liver disease.
Read MoreMAFLD biomarkers: a review
Authors: Alharthi J, Eslam M.
Published in J Clin Transl Hepatol 2022
The identification of high-risk MAFLD patients is paramount. Liver biopsy is still considered the gold standard for the assessment of patients with MAFLD. The search for noninvasive biomarkers .....
Read MoreNAFLD/NASH: clinically relevant adipose tissue measurement techniques
Authors: Vilalta A, Gutiérrez JA, Chaves S, et al.
Published in Endocrinol Diabetes Metab 2022
The body mass index (BMI) is commonly used as a proxy measure of body fatness. However, BMI does not reflect the level and distribution of body fat. .....
Read MoreB cells aggravate NASH: an innate and adaptive signalling
Authors: Barrow F, Khan S, Fredrickson G, et al.
Published in Hepatology 2021
In this study, F. Barrow et al. (University of Minnesota Medical School, Minneapolis, USA) report that NASH livers accumulate B cells with elevated pro-inflammatory cytokine secretion .....
Read MoreNAFLD: from drivers to targets
Authors: antos-Laso A, Gutiérrez-Larrañaga M, Alonso-Peña M, et al.
Published in Biomedicines 2021
In this review, A. Santos-Laso et al. (Marqués de Valdecilla University Hospital, Valdecilla Biomedical Research Institute, Santander, Spain) summarise the key aspects of NAFLD .....
Read MoreNASH: an Overview Through 200 Years of Clinical Research
Authors: Geier A, Tiniakos D, Denk H, et al.
Published in Gut 2021
Although the term 'fatty liver hepatitis' first appeared in 1962, it was in 1980 that the term 'non-alcoholic steatohepatitis' (NASH) was coined and the histopathological.....
Read MoreImmune cell-mediated features of NASH
Authors: Huby T, Gautier EL.
Published in Nat Rev Immunol 2022
In this review, T. Huby and E. L. Gautier (Sorbonne Université, Hôpital de la Pitié-Salpêtrière, Paris, France) discuss “current concepts related to the.....
Steatohepatitis: hypothesis for a pathomechanism
Authors: Abuja PM, Zatloukal K, Denk H.
Published in Int J Mol Sci 2021
In this article, P. M. Abuja et al. (Medical University of Graz, Austria) propose that steatohepatitis develops in four phases with transitions, priming triggering, adaptation....
Read MoreFatty liver through the ages: Nonalcoholic steatohepatitis
Authors: Younossi ZM, Henry L.
Published in Endocr Pract 2022
In this article, Z. M. Younossi et al. (Inova Health System, Falls Church, VA, USA) aimed to review the current literature on NAFLD and NASH as it impacts children and adults....
Read More